Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action filed by Robbins Geller Rudman & Dowd LLP
Soleno TherapeuticsSoleno Therapeutics(US:SLNO) Businesswire·2026-03-13 17:10

文章核心观点 - 针对Soleno Therapeutics公司的诉讼指控其关于DCCR的第三阶段临床试验项目淡化了、歪曲了和/或隐瞒了安全性问题 [1] 公司相关事件 - 诉讼指控Soleno公司在其DCCR的第三阶段临床试验项目中存在不当行为 [1] - 被指控的具体行为包括淡化、歪曲和/或隐瞒该临床试验项目的安全性问题 [1]

Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action filed by Robbins Geller Rudman & Dowd LLP - Reportify